Juno ROCKETs On Fast Clinical Hold Resolution

The FDA lifted a clinical hold on the Phase II ROCKET clinical trial for Juno's lead CAR-T therapy candidate JCAR015 less than a week after it was instituted, allowing the company to proceed without using fludarabine in a pre-conditioning chemotherapy regimen.

Juno Therapeutics Inc. soared in after-hours trading on July 12 following the company's late-day announcement that a clinical hold on its Phase II ROCKET clinical trial for the chimeric antigen receptor T-cell (CAR-T) therapy JCAR015 has been lifted just a few business days after the US FDA instituted the hold in response to three deaths in the study.

Seattle, Washington-based Juno fell more than 27% after the stock market closed on July 7 when the company first revealed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins

05 Jun 2025

• By Mandy Jackson

Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.